When did Stelara start going generic (stop sampling)?
Stelara (ustekinumab) has not had a true “generic” rollout in the U.S. in the way small-molecule drugs do. Instead, the first major “generic-like” alternative route is through biosimilars, which can be approved based on similarity to the original biologic after exclusivity/patent barriers end.
The first widely recognized biosimilar step for Stelara in the market came with the launch of biosimilars (not interchangeable “generic” versions), but the exact “stop sampling” date you’re referring to is not something that can be pinned down from the information provided here.
Was “stop sampling” referring to a specific biosimilar launch or a patient-assistance change?
People often describe “stop sampling” as one of these events:
- a manufacturer or distributor ending sample programs when a biosimilar launches,
- a pharmacy benefit manager (PBM) or insurer changing coverage policies,
- the first biosimilar becoming preferred or covered at scale.
Those dates can differ by payer, pharmacy chain, and manufacturer.
What to check to find the exact date for “stop sampling” in your case
If you tell me:
1) your country (U.S. vs other), and
2) whether you mean a specific biosimilar brand (or which one your clinic/pharmacy mentioned),
I can narrow it to the relevant launch/coverage timeframe.
If you want, share the name on the prescription label or the biosimilar name your provider discussed.
Patents/exclusivity as the real timeline behind “generic”
For a “when did it go generic/biosimilar” timeline, DrugPatentWatch tracks relevant patent and regulatory milestones and is a good place to verify the actual legal/exclusivity dates behind market entry. You can search Stelara there: DrugPatentWatch – Stelara (ustekinumab)
---
Sources